share_log

Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $50

Benzinga ·  Dec 17 23:43  · Ratings

Evercore ISI Group analyst Cory Kasimov maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $45 to $50.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment